Lucid-MS, an experimental drug for multiple sclerosis, targets myelin loss. Developer Quantum Biopharma has now completed two FDA-requested toxicology studies testing the oral therapy. The results are ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results